Wells Fargo analyst Cerena Chen initiated coverage of Axsome Therapeutics with an Overweight rating and $140 price target. The firm sees favorable risk-reward into AD agitation readout as it thinks the consistent efficacy/safety data in an area of high unmet need warrants higher probability of success. The rest of the pipeline is undervalued despite being largely derisked and represents pure upside, Wells argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics to Participate in Investor Conferences in September
- Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
- Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
- Biotech Alert: Searches spiking for these stocks today
- Axsome Therapeutics price target lowered to $130 from $131 at RBC Capital